Skip to main content
GameRevenueData

Publisher

Games Published by LU QI: Revenue & Sales Estimates

Revenue estimates for the 7 Steam games published by LU QI, ranked by estimated net revenue. Available estimated lifetime net (USD): $13.7K.

Catalog Est. Lifetime Net (USD)

$13.7K

Estimates for 7 of 7 tracked games

Tracked games

7

Top Earner

祛魅·格心(祛魅3)

$3.4K

Coverage: 7 tracked titles; 7 with net estimates; 0 without. 0 have dedicated profiles. Missing estimates are excluded from the aggregate, not treated as known zero revenue.

Role: Publisher. These are lifetime estimates for games credited to LU QI; they are not company earnings, profit, or contractual receipts. Credits may omit co-development or historical publishing arrangements. Developer and publisher identities are not merged by matching names.

Recorded release dates: 2018-05-08–2025-01-08 (may include announced dates).

Largest title accounts for 24.5% of available estimated net revenue. Coverage gaps can change this share.

Showing 1–7 of the top 7 displayed entries, from 7 tracked titles. Figures include only available estimates. Search the full catalog .

Rows 1–7 · Page 1 of 1

# Game Est. lifetime net (USD) Positive reviews (raw) Release
1 祛魅·格心(祛魅3) $3.4K 69%Mixed (49) Aug 2, 2021
2 祛魅·入灭(祛魅2) $2.6K 75%Positive (55) Nov 14, 2018
3 祛魅·化始(祛魅4) $2.6K 95%Positive (22) Jan 8, 2025
4 祛魅·教化(祛魅1) $2.6K 74%Positive (109) May 8, 2018
5 末日竟在我身边 - Zombies Everywhere $1.9K 79%Positive (81) Jan 25, 2021
6 末日竟在我身边2 - Zombies Everywhere 2 $423 100%Positive (18) Sep 30, 2021
7 末日竟在我身边3 - Zombies Everywhere 3 $259 91%Positive (11) Sep 30, 2022

Get real-time dashboards, historical trends, and AI-powered analysis

Explore on PlayRev(opens in new tab)

Revenue and sales estimates are based on the Boxleiter method using publicly available data including Steam review counts, pricing history, and statistical modeling. Actual revenue may differ significantly. These figures are provided for informational purposes only and should not be used for financial decisions. Read the full methodology.